Unknown

Dataset Information

0

Long-Term Follow-Up of 90Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation-Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma.


ABSTRACT: Nonmyeloablative allogeneic hematopoietic cell transplantation (HCT) can provide prolonged remissions in patients with advanced B cell lymphoma (B-NHL) via the graft-versus-lymphoma effect, although inferior results are seen in patients with chemoresistant, bulky, or aggressive disease. Radioimmunotherapy can safely induce responses in B-NHL with minimal nonhematologic toxicity. Initial results of 90Y-ibritumomab tiuxetan-based allografting demonstrated early safety and disease control in nonremission patients but with short follow-up. Here we report the long-term outcomes of patients treated on this study with specific emphasis on patients achieving early remissions. Eleven of 40 patients were alive at a median follow-up of 9 years (range, 5.3 to 10.2). Fourteen (35%) deaths were due to disease progression and 14 (35%) deaths to complications from HCT. One patient died of a Merkel cell carcinoma. The 5-year overall and progression-free survival for patients with indolent B-NHL was 40% and 27.5%, respectively. None of the patients with diffuse large B cell lymphoma was a long-term disease-free survivor regardless of early remission status. 90Y-ibritumomab tiuxetan-based allografting represents a viable option in patients with indolent histologies. Improved strategies are needed for aggressive B-NHL. The original trial was registered at www.clinicaltrials.gov as NCT00119392.

SUBMITTER: Puronen CE 

PROVIDER: S-EPMC6251312 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Long-Term Follow-Up of <sup>90</sup>Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation-Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma.

Puronen Camille E CE   Cassaday Ryan D RD   Stevenson Philip A PA   Sandmaier Brenda M BM   Flowers Mary E ME   Green Damian J DJ   Maloney David G DG   Storb Rainer F RF   Press Oliver W OW   Gopal Ajay K AK  

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20180703 11


Nonmyeloablative allogeneic hematopoietic cell transplantation (HCT) can provide prolonged remissions in patients with advanced B cell lymphoma (B-NHL) via the graft-versus-lymphoma effect, although inferior results are seen in patients with chemoresistant, bulky, or aggressive disease. Radioimmunotherapy can safely induce responses in B-NHL with minimal nonhematologic toxicity. Initial results of <sup>90</sup>Y-ibritumomab tiuxetan-based allografting demonstrated early safety and disease contro  ...[more]

Similar Datasets

| S-EPMC3673760 | biostudies-literature
| S-EPMC4884941 | biostudies-literature
| S-EPMC4347306 | biostudies-literature
| S-EPMC4509863 | biostudies-literature
| S-EPMC4031906 | biostudies-literature
| S-EPMC8753215 | biostudies-literature
| S-EPMC5743624 | biostudies-literature
| S-EPMC3951424 | biostudies-literature
| S-EPMC5646666 | biostudies-literature
| S-EPMC6712526 | biostudies-literature